Följ
Hannes Hagström
Hannes Hagström
Verifierad e-postadress på ki.se
Titel
Citeras av
Citeras av
År
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
M Ekstedt, H Hagström, P Nasr, M Fredrikson, P Stål, S Kechagias, ...
Hepatology 61 (5), 1547-1554, 2015
21832015
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis
PS Dulai, S Singh, J Patel, M Soni, LJ Prokop, Z Younossi, G Sebastiani, ...
Hepatology 65 (5), 1557-1565, 2017
16262017
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ...
Journal of hepatology 67 (6), 1265-1273, 2017
9042017
Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis
G Musso, R Gambino, JH Tabibian, M Ekstedt, S Kechagias, ...
PLoS medicine 11 (7), e1001680, 2014
7012014
Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis
RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ...
Gastroenterology 158 (6), 1611-1625. e12, 2020
6992020
Advancing the global public health agenda for NAFLD: a consensus statement
JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ...
Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022
4132022
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
TG Simon, B Roelstraete, H Khalili, H Hagström, JF Ludvigsson
Gut 70 (7), 1375-1382, 2021
3522021
Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long‐term follow‐up study
H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ...
Hepatology communications 2 (1), 48-57, 2018
2492018
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study
GJ Webb, T Marjot, JA Cook, C Aloman, MJ Armstrong, EJ Brenner, ...
The lancet Gastroenterology & hepatology 5 (11), 1008-1016, 2020
2472020
NASH in lean individuals
R Younes, E Bugianesi
Seminars in liver disease 39 (01), 086-095, 2019
2272019
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
T Brevini, M Maes, GJ Webb, BV John, CD Fuchs, G Buescher, L Wang, ...
Nature 615 (7950), 134-142, 2023
1462023
Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease
H Hagström, M Talbäck, A Andreasson, G Walldius, N Hammar
Gastroenterology 158 (1), 200-214, 2020
1362020
Adaptation of the Charlson comorbidity index for register-based research in Sweden
JF Ludvigsson, P Appelros, J Askling, L Byberg, JJ Carrero, AM Ekström, ...
Clinical epidemiology, 21-41, 2021
1272021
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort
TG Simon, B Roelstraete, H Hagström, J Sundström, JF Ludvigsson
Gut 71 (9), 1867-1875, 2022
1252022
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
H Hagström, M Talbäck, A Andreasson, G Walldius, N Hammar
Journal of hepatology 73 (5), 1023-1029, 2020
1212020
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet–a randomised controlled trial
M Holmer, C Lindqvist, S Petersson, J Moshtaghi-Svensson, V Tillander, ...
JHEP Reports 3 (3), 100256, 2021
1192021
Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population
TG Simon, AS Duberg, S Aleman, H Hagstrom, LH Nguyen, H Khalili, ...
Annals of internal medicine 171 (5), 318-327, 2019
1162019
Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement
H Hagström, LA Adams, AM Allen, CD Byrne, Y Chang, H Grønbæk, ...
Hepatology 74 (1), 474-482, 2021
1082021
Cancer risk in patients with biopsy‐confirmed nonalcoholic fatty liver disease: a population‐based cohort study
TG Simon, B Roelstraete, R Sharma, H Khalili, H Hagström, ...
Hepatology 74 (5), 2410-2423, 2021
1052021
Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis
C Efe, H Hagström, H Ytting, RA Bhanji, NF Müller, Q Wang, T Purnak, ...
Clinical Gastroenterology and Hepatology 15 (12), 1950-1956. e1, 2017
1052017
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20